Therapy
Belimumab
Human IgG1λ anti-BAFF/BLyS mAb: neutralises soluble BAFF → reduces B cell survival signal → autoreactive B cells more likely to undergo apoptosis.
Also called: Benlysta, anti-BLyS, anti-BAFF
In short
- 1What it is: a therapy in therapies and applications.
- 2How it connects: acts on 3 and is affected by 1 concepts — mostly 1 molecule, 2 disease, 1 trial.
- 3Where it sits: therapy, trial on the 15-step immune chain.
What it does
First biologic approved for SLE in 50 years (BLISS-52/76 2011): annualised flare rate -48% vs placebo; best in: IFN-high + elevated anti-dsDNA + active non-renal SLE + elevated BAFF at baseline; HCQ must continue; SC formulation (200mg weekly) enables home administration.
Its connections at a glance
Each dot is a concept directly linked to Belimumab. Colours show the kind of concept.
Sources & evidenceloading…
Loading reviewed sources…
Graph ID I018 · concept status: established. Select any connection above to inspect evidence for that specific link.